{"id":11763,"date":"2017-12-04T16:24:08","date_gmt":"2017-12-04T15:24:08","guid":{"rendered":"https:\/\/news.embl.de\/?p=11763"},"modified":"2024-03-22T11:52:56","modified_gmt":"2024-03-22T10:52:56","slug":"takeda-joins-open-targets-drug-target-discovery-initiative","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/","title":{"rendered":"Takeda joins drug target discovery initiative"},"content":{"rendered":"\n<p>Takeda is a global, research and development-driven pharmaceutical company&nbsp;with expertise in oncology, gastroenterology (GI) and central nervous system (CNS) disease that will complement the offerings of GSK, Biogen, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), and build on the initiative\u2019s success.<\/p>\n\n\n\n<p>Open Targets is a unique, precompetitive partnership between companies and not-for-profit research institutes. It was set up to systematically improve the identification and prioritisation of drug targets for safe and effective medicines. The freely available <a href=\"http:\/\/www.targetvalidation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Open Targets Platform<\/a> makes it easy for researchers working in many disciplines to identify and prioritise therapeutic targets for new medicines. Underscoring its utility for drug discovery, the platform features over 26,000 targets associated with more than 9,000 diseases. The resource has had over 82,000 visits since its launch.<\/p>\n\n\n\n<p>Approximately 90 percent of compounds entering clinical trials never make it to the market. This is an extremely costly and time-consuming process, which often fails because the biological target chosen is not well understood.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Innovative medicines<\/h2>\n\n\n\n<p>To address this challenge, Open Targets combines the skills, knowledge and technologies of its partner organisations, offering a critical mass of expertise that does not exist in any single institution. Large-scale genomic experiments (Sanger Institute) and computational techniques (EMBL-EBI) developed in the public domain are blended with formal pharmaceutical R&amp;D approaches to identify causal links between targets, pathways and diseases. This enables the partners to systematically identify drug targets, and prioritise them for further exploration.<\/p>\n\n\n\n<p>\u201cTakeda is committed to reverse translation using human genetics and genomics to discover and validate the next generation of targets to innovative medicines,\u201d says John Wagner, Senior Vice President and Head of Translational Research and Early Clinical at Takeda. \u201cThe collaboration with Open Targets \u2013 using its comprehensive informatics platform and the accessibility of a vast array of latest innovative experimental platforms for rapid assessment and validation of potential targets \u2013 will accelerate Takeda\u2019s capabilities to identify and validate human targets with robust scientific support. Takeda brings deep scientific expertise in neuroscience, GI, and oncology to the collaboration, well-aligned with the priorities of Open Targets.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Research community<\/h2>\n\n\n\n<p>\u201cWe believe that target identification and prioritisation can be improved, but no one entity can do it alone,\u201d says Jeff Barrett, Director of Open Targets. \u201cTakeda\u2019s insight, expertise and skills will enhance our ability to crack a very difficult problem \u2013 how to find the best targets for new medicines, effectively and efficiently, and share them openly with the research community.\u201d<\/p>\n\n\n\n<p>Open Targets covers all aspects of human health and disease. The cornerstone of the collaboration is an agreement that experimental data and information gathered within the initiative will be shared openly, to benefit the broader scientific community.<\/p>\n\n\n\n<p>Open Targets welcomes new interest from companies and academic institutions that wish to accelerate the discovery of drug targets through open innovation.<\/p>\n\n\n\n<p>This post was originally published on <a href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/takeda-joins-drug-target-discovery-initiative\" target=\"_blank\" rel=\"canonical nofollow noopener noreferrer\" data-href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/takeda-joins-drug-target-discovery-initiative\">EMBL-EBI News.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda joins pioneering public-private drug discover collaboration Open Targets<\/p>\n","protected":false},"author":47,"featured_media":11765,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3,17593],"tags":[28,312,36,155,71],"embl_taxonomy":[],"class_list":["post-11763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lab-matters","category-people-perspectives","tag-bioinformatics","tag-drug-discovery","tag-embl-ebi","tag-gsk","tag-industry"],"acf":{"article_intro":"<p>Takeda joins pioneering public-private drug discovery collaboration Open Targets<\/p>\n","related_links":[{"link_description":"Takeda","link_url":"https:\/\/www.takeda.com\/"},{"link_description":"Open Targets","link_url":"https:\/\/www.opentargets.org\/"},{"link_description":"EMBL-EBI","link_url":"https:\/\/www.ebi.ac.uk\/"}],"article_sources":false,"vf_locked":false,"featured":false,"color":"#007B53"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Takeda joins Open Targets drug target discovery initiative<\/title>\n<meta name=\"description\" content=\"Pharmaceutical company Takeda joins Open Targets, the public-private drug target discovery initiative.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda joins Open Targets drug target discovery initiative\" \/>\n<meta property=\"og:description\" content=\"Pharmaceutical company Takeda joins Open Targets, the public-private drug target discovery initiative.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-04T15:24:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T10:52:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1044\" \/>\n\t<meta property=\"og:image:height\" content=\"637\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oana Stroe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Oana Stroe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\"},\"author\":{\"name\":\"Oana Stroe\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\"},\"headline\":\"Takeda joins drug target discovery initiative\",\"datePublished\":\"2017-12-04T15:24:08+00:00\",\"dateModified\":\"2024-03-22T10:52:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\"},\"wordCount\":481,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg\",\"keywords\":[\"bioinformatics\",\"drug discovery\",\"embl-ebi\",\"gsk\",\"industry\"],\"articleSection\":[\"Lab Matters\",\"People &amp; Perspectives\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\",\"url\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\",\"name\":\"Takeda joins Open Targets drug target discovery initiative\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg\",\"datePublished\":\"2017-12-04T15:24:08+00:00\",\"dateModified\":\"2024-03-22T10:52:56+00:00\",\"description\":\"Pharmaceutical company Takeda joins Open Targets, the public-private drug target discovery initiative.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg\",\"width\":1044,\"height\":637,\"caption\":\"Takeda joins public-private drug target discovery initiative Open Targets. PHOTO: Takeda\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\",\"name\":\"Oana Stroe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"caption\":\"Oana Stroe\"},\"description\":\"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.\",\"url\":\"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Takeda joins Open Targets drug target discovery initiative","description":"Pharmaceutical company Takeda joins Open Targets, the public-private drug target discovery initiative.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/","og_locale":"en_US","og_type":"article","og_title":"Takeda joins Open Targets drug target discovery initiative","og_description":"Pharmaceutical company Takeda joins Open Targets, the public-private drug target discovery initiative.","og_url":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2017-12-04T15:24:08+00:00","article_modified_time":"2024-03-22T10:52:56+00:00","og_image":[{"width":1044,"height":637,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","type":"image\/jpeg"}],"author":"Oana Stroe","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Oana Stroe","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/"},"author":{"name":"Oana Stroe","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414"},"headline":"Takeda joins drug target discovery initiative","datePublished":"2017-12-04T15:24:08+00:00","dateModified":"2024-03-22T10:52:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/"},"wordCount":481,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","keywords":["bioinformatics","drug discovery","embl-ebi","gsk","industry"],"articleSection":["Lab Matters","People &amp; Perspectives"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/","url":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/","name":"Takeda joins Open Targets drug target discovery initiative","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","datePublished":"2017-12-04T15:24:08+00:00","dateModified":"2024-03-22T10:52:56+00:00","description":"Pharmaceutical company Takeda joins Open Targets, the public-private drug target discovery initiative.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","width":1044,"height":637,"caption":"Takeda joins public-private drug target discovery initiative Open Targets. PHOTO: Takeda"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414","name":"Oana Stroe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","caption":"Oana Stroe"},"description":"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.","url":"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2017\/12\/Press_release_Takeda_joins_Open_Targets.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/11763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=11763"}],"version-history":[{"count":8,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/11763\/revisions"}],"predecessor-version":[{"id":21629,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/11763\/revisions\/21629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/11765"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=11763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=11763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=11763"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=11763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}